

Supplementary Documents [IFRS]

Financial results for the first six months of the fiscal year 2016 (FY2016)

Astellas Pharma Inc.

- Q2/FY2016 Financial Results
 - Six months ended September 30, 2016
 - Three months ended September 30, 2016
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Six months ended September 30, 2016]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)	FY15 Full Year	Initial Forecasts FY16 Full Year	Revised Forecasts FY16 Full Year	Change from FY15 Change (%)
Sales	687.5	651.7	-35.8	-5.2%	1,372.7	1,350.0	1,300.0	-5.3%
Cost of sales	168.4	146.2	-22.2	-13.2%	335.6			
Ratio to Sales	24.5%	22.4%			24.4%			
Gross profit	519.1	505.5	-13.6	-2.6%	1,037.1			
SG&A expenses	239.7	220.8	-18.9	-7.9%	500.4			
Ratio to Sales	34.9%	33.9%			36.5%			
Advertising and Sales Promotion	83.3	69.2	-14.1	-16.9%	169.1			
Personnel expenses	91.3	85.5	-5.8	-6.4%	186.1			
Other	65.1	66.2	1.0	1.6%	145.1			
R&D expenses	112.0	99.7	-12.4	-11.0%	225.7	231.0	216.0	-4.3%
Ratio to Sales	16.3%	15.3%			16.4%	17.1%	16.6%	
Amortisation of intangible assets	21.9	17.7	-4.2	-19.2%	42.4			
Share of profits/losses of associates and joint ventures	-0.3	-0.8	-0.5	-	-1.2			
Other income	0.9	0.4	-0.5	-57.6%	1.7			
Gain on sales of property, plant and equipment	0.2	0.0	-0.2	-89.7%	0.3			
Other expense	13.4	9.8	-3.6	-27.2%	20.2			
Loss on sales and disposal of property, plant and equipment	0.3	0.2	-0.1	-23.8%	0.7			
Impairment losses	6.6	7.6	1.0	16.0%	9.5			
Net foreign exchange losses	5.9	0.5	-5.4	-91.5%	7.0			
Operating profit	132.6	157.1	24.4	18.4%	249.0	267.0	267.0	7.2%
Ratio to Sales	19.3%	24.1%			18.1%	19.8%	20.5%	
Finance income	13.3	2.4	-11.0	-82.1%	14.4			
Gain on sales of available-for-sale financial assets	12.1	1.6	-10.5	-86.9%	12.3			
Finance expense	0.6	1.7	1.1	194.7%	1.6			
Impairment losses for available-for-sale financial assets	0.1	0.4	0.3	263.1%	0.4			
Profit before tax	145.4	157.8	12.4	8.5%	261.8	268.0	268.0	2.4%
Ratio to Sales	21.2%	24.2%			19.1%	19.9%	20.6%	
Income tax expense	42.5	42.7	0.2	0.5%	68.1			
Profit for the period	102.9	115.1	12.1	11.8%	193.7	197.0	198.0	2.2%
Ratio to Sales	15.0%	17.7%			14.1%	14.6%	15.2%	
Comprehensive income	104.9	2.7	-102.2	-97.5%	130.9			

Unit: B¥

2. Consolidated Results (Core Basis)

	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
Sales	687.5	651.7	-35.8	-5.2%
Cost of sales	168.4	146.2	-22.2	-13.2%
	Ratio to Sales	24.5%	22.4%	
Gross profit	519.1	505.5	-13.6	-2.6%
SG&A expenses	239.7	220.8	-18.9	-7.9%
	Ratio to Sales	34.9%	33.9%	
Advertising and Sales Promotion	83.3	69.2	-14.1	-16.9%
Personnel expenses	91.3	85.5	-5.8	-6.4%
Other	65.1	66.2	1.0	1.6%
R&D expenses	112.0	99.7	-12.4	-11.0%
	Ratio to Sales	16.3%	15.3%	
Amortisation of intangible assets	21.9	17.7	-4.2	-19.2%
Share of profits/losses of associates and joint ventures	-0.3	-0.8	-0.5	-
Operating profit	145.2	166.5	21.3	14.7%
	Ratio to Sales	21.1%	25.5%	
Finance income	1.3	0.8	-0.5	-37.8%
Finance expense	0.3	1.3	1.0	327.2%
Profit before Tax	146.2	166.0	19.8	13.6%
	Ratio to Sales	21.3%	25.5%	
Income tax expense	42.2	45.4	3.2	7.5%
Profit for the period	103.9	120.6	16.6	16.0%
	Ratio to Sales	15.1%	18.5%	

	Initial Forecasts	Revised Forecasts	Change from FY15
	FY16 Full Year	FY16 Full Year	Change (%)
	1,372.7	1,350.0	-5.3%
	335.6		
	24.4%		
	1,037.1		
	500.4		
	36.5%		
	169.1		
	186.1		
	145.1		
	225.7	231.0	-4.3%
	16.4%	17.1%	
	42.4	216.0	
	-1.2	16.6%	
	267.5	270.0	2.4%
	19.5%	20.0%	
	2.1	274.0	
	1.0	21.1%	
	268.6		
	19.6%		
	69.8		
	198.8	199.0	1.6%
	14.5%	14.7%	
		202.0	
		15.5%	

3. Exchange Rate

Unit: yen

	FY15 APR. - SEP.Ave.	FY16 APR. - SEP.Ave.	FY15 End	FY16 2Q End
USD/Yen	122	105	113	101
EUR/Yen	135	118	128	113

	Initial Forecasts	Revised Forecasts
	FY16 Full Year	FY16 Full Year
	120	110
	133	103
		125
		117

* Exchange rate fluctuations had negative impact by 64.1 billion yen on sales and negative impact by 12.5 billion yen on Core operating profit in Q2/FY2016

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY15 APR. - SEP.			FY16 APR. - SEP.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	687.5	-	687.5	651.7	-	651.7
Cost of sales	168.4	-	168.4	146.2	-	146.2
Gross profit	519.1	-	519.1	505.5	-	505.5
SG&A expenses	239.7	-	239.7	220.8	-	220.8
R&D expenses	112.0	-	112.0	99.7	-	99.7
Amortisation of intangible assets	21.9	-	21.9	17.7	-	17.7
Share of losses of associates and joint ventures	-0.3	-	-0.3	-0.8	-	-0.8
Other income *1	0.9	-0.9	-	0.4	-0.4	-
Other expense *1	13.4	-13.4	-	9.8	-9.8	-
Operating profit	132.6	12.5	145.2	157.1	9.4	166.5
Finance income *2	13.3	-12.1	1.3	2.4	-1.6	0.8
Finance expense *2	0.6	-0.3	0.3	1.7	-0.4	1.3
Profit before tax	145.4	0.7	146.2	157.8	8.2	166.0
Income tax expense	42.5	-0.3	42.2	42.7	2.7	45.4
Profit for the period	102.9	1.0	103.9	115.1	5.5	120.6

*1. "Other income" and "Other expense" are excluded from Core results.

"Other income" and "Other expense" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale ("AFS") and impairment losses of AFS included in "Finance income" and "Finance expense" are excluded from Core results as non-core items.

5. Sales by Region

Unit: B¥

		FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
Sales		687.5	651.7	-35.8	-5.2%
Japan		247.1	237.2	-10.0	-4.0%
	Ratio to Sales	35.9%	36.4%		
Americas		232.9	206.6	-26.2	-11.3%
	Ratio to Sales	33.9%	31.7%		
EMEA		162.3	166.1	3.8	2.3%
	Ratio to Sales	23.6%	25.5%		
Asia and Oceania		45.2	41.8	-3.4	-7.6%
	Ratio to Sales	6.6%	6.4%		

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

FY15 Full Year
1,372.7
497.2
36.2%
455.1
33.2%
329.3
24.0%
91.1
6.6%

Initial Forecasts	Revised Forecasts	Change from FY15
FY16 Full Year	FY16 Full Year	Change (%)
1,350.0	1,300.0	-5.3%
480.8	483.7	-2.7%
35.6%	37.2%	
441.2	409.1	-10.1%
32.7%	31.5%	
339.6	322.1	-2.2%
25.2%	24.8%	
88.3	85.1	-6.6%
6.5%	6.5%	

6 Per Share Information

	FY15 APR. - SEP.	FY16 APR. - SEP.
The number of shares issued (thousand)	2,221,823	2,153,823
Treasury Shares (thousand)	64,020	29,169
The number of shares issued after deducting Treasury Shares (thousand)	2,157,802	2,124,653
Earnings per share (yen)	47.30	54.16
Earnings per share (yen) core base	47.76	56.75
Dividend per share (yen)	16	17

FY15 Full Year
2,221,823
96,844
2,124,978
89.75
92.12
32

Initial Forecasts	Revised Forecasts
FY16 Full Year	FY16 Full Year
92.71	93.19
93.65	95.07
34	34

7. Addition to Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
Addition to Property, Plant and Equipment					
	Consolidated	18.4	8.9	-9.5	-51.5%
Depreciation (PP&E)					
	Consolidated	10.2	10.9	0.6	6.3%
Amortisation (Intangible Assets) *					
	Consolidated	24.8	20.6	-4.2	-17.1%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

FY15 Full Year
34.0
21.0
48.2

Initial Forecasts	Revised Forecasts	Change from FY15
FY16 Full Year	FY16 Full Year	Change (%)
32.0	26.0	-23.6%
22.0	22.0	5.0%
43.5	41.0	-15.0%

8. Sales of major products

1) Sales of global products

Unit: B¥

	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
XTANDI	122.3	126.0	3.6	3.0%
US	74.5	68.3	-6.2	-8.3%
ex-US	47.9	57.7	9.8	20.4%
Japan	13.1	11.8	-1.3	-9.9%
Americas (ex-US)	2.3	3.5	1.3	56.6%
EMEA	31.5	40.8	9.2	29.3%
Asia and Oceania	1.0	1.6	0.6	53.8%
Eligard	8.8	7.9	-1.0	-10.9%
EMEA	8.7	7.7	-1.0	-11.5%
Asia and Oceania	0.1	0.1	0.0	40.3%
Vesicare	69.7	59.8	-9.9	-14.2%
Japan	13.3	13.0	-0.3	-2.4%
Americas	33.3	27.7	-5.6	-16.9%
EMEA	20.3	16.6	-3.8	-18.5%
Asia and Oceania	2.6	2.4	-0.3	-9.8%
Betanis/Myrbetriq/BETMIGA	38.1	45.7	7.6	20.0%
Japan	9.7	12.4	2.6	27.0%
Americas	21.4	25.1	3.6	16.9%
EMEA	6.6	6.9	0.2	3.6%
Asia and Oceania	0.3	1.4	1.2	445.4%
Harnal/Omnic	27.1	23.5	-3.7	-13.5%
Sales by Astellas	25.7	22.5	-3.2	-12.3%
Japan	6.7	4.8	-1.9	-27.8%
EMEA	8.0	6.8	-1.2	-15.5%
Asia and Oceania	10.6	10.5	-0.1	-1.2%
Bulk and Royalties	1.5	1.0	-0.5	-33.9%
Prograf	104.6	94.2	-10.4	-10.0%
Sales by Astellas	103.1	92.6	-10.5	-10.2%
Japan (Including Graceptor)	25.4	24.8	-0.6	-2.4%
Americas	18.1	14.1	-4.0	-22.1%
EMEA	40.1	35.7	-4.5	-11.1%
Advagraf	15.8	15.0	-0.8	-5.1%
Asia and Oceania	19.4	18.0	-1.4	-7.4%
Exports to third parties	1.5	1.6	0.1	6.5%
Funguard/MYCAMINE	21.1	20.1	-1.0	-4.5%
Japan	6.1	5.6	-0.4	-7.0%
Americas	6.7	6.0	-0.7	-11.0%
EMEA	5.6	5.6	-0.0	-0.9%
Asia and Oceania	2.7	3.0	0.2	9.2%

- Sales of products in Japan are shown in a gross sales basis.

- EMEA: Europe, Middle East and Africa

Unit: B¥

	FY15 Full Year	Initial Forecasts FY16 Full Year	Revised Forecasts FY16 Full Year	Change from FY15 Change (%)
XTANDI	252.1	295.9	265.7	5.4%
US	148.4	163.7	143.7	-3.1%
ex-US	103.7	132.2	122.0	17.6%
Japan	26.2	25.7	24.3	-7.2%
Americas (ex-US)	4.5	6.1	7.2	59.9%
EMEA	70.7	95.9	86.8	22.9%
Asia and Oceania	2.4	4.5	3.7	54.9%
Eligard	17.6	17.6	15.3	-12.9%
EMEA	17.4	17.3	15.0	-13.5%
Asia and Oceania	0.2	0.3	0.3	35.9%
Vesicare	135.6	119.1	114.9	-15.3%
Japan	26.5	27.2	26.1	-1.5%
Americas	63.7	53.7	51.0	-19.9%
EMEA	39.8	32.4	32.5	-18.4%
Asia and Oceania	5.3	5.4	5.1	-3.0%
Betanis/Myrbetriq/BETMIGA	81.7	100.4	95.1	16.4%
Japan	21.2	27.4	26.9	26.6%
Americas	45.7	51.9	50.6	10.7%
EMEA	13.4	18.3	14.5	8.5%
Asia and Oceania	1.4	2.8	3.1	117.0%
Harnal/Omnic	53.4	46.4	44.1	-17.5%
Sales by Astellas	50.4	44.2	42.1	-16.4%
Japan	12.7	9.4	9.0	-28.7%
EMEA	15.4	13.7	13.2	-14.2%
Asia and Oceania	21.5	20.5	19.9	-7.7%
Bulk and Royalties	3.0	2.2	1.9	-35.5%
Prograf	203.6	187.9	182.9	-10.2%
Sales by Astellas	200.7	185.4	180.5	-10.1%
Japan (Including Graceptor)	49.8	47.8	48.4	-2.7%
Americas	34.6	26.9	26.6	-23.3%
EMEA	77.9	73.6	68.7	-11.8%
Advagraf	31.1	37.1	36.8	-4.3%
Asia and Oceania	38.4	37.1	36.8	-4.3%
Exports to third parties	2.8	2.5	2.4	-14.9%
Funguard/MYCAMINE	41.6	40.4	38.2	-8.3%
Japan	11.7	11.5	11.0	-5.7%
Americas	13.0	11.8	11.1	-14.7%
EMEA	11.2	11.2	10.3	-8.5%
Asia and Oceania	5.7	6.0	5.8	1.7%

2) Sales of products in Japan

Unit: B¥

	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
<Global products>				
XTANDI	13.1	11.8	-1.3	-9.9%
Vesicare	13.3	13.0	-0.3	-2.4%
Betanis	9.7	12.4	2.6	27.0%
Harnal	6.7	4.8	-1.9	-27.8%
Prograf (Including Graceptor)	25.4	24.8	-0.6	-2.4%
Funguard	6.1	5.6	-0.4	-7.0%
<Local products in Japan>				
Micardis [Family]	48.5	46.8	-1.7	-3.5%
Micombi	5.1	4.8	-0.4	-7.4%
Micamlo	12.7	13.0	0.3	2.0%
Celecox	23.4	24.1	0.7	3.0%
Symbicort	17.5	18.7	1.1	6.5%
Bonoteo	7.1	7.0	-0.1	-1.0%
Geninax	4.8	4.2	-0.5	-11.2%
Vaccines	14.0	11.1	-2.9	-20.7%
Argamate	3.1	3.0	-0.1	-3.6%
Kiklin	0.8	0.8	-0.0	-6.0%
Gonax	1.9	2.2	0.2	12.7%
Cimzia	3.2	3.9	0.6	19.6%
Suglat	3.5	4.6	1.1	32.8%
Lipitor	16.3	12.2	-4.1	-25.3%
Myslee	9.2	7.6	-1.6	-17.9%
Gaster	7.7	5.6	-2.1	-27.5%
Seroquel	5.7	4.1	-1.6	-28.5%
Total Rx Sales In Japanese market	240.0	221.8	-18.2	-7.6%

- Sales of products in Japan are shown in a gross sales basis.

FY15 Full Year	Initial Forecasts	Revised Forecasts	Change from FY15
	FY16 Full Year	FY16 Full Year	Change (%)
26.2	25.7	24.3	-7.2%
26.5	27.2	26.1	-1.5%
21.2	27.4	26.9	26.6%
12.7	9.4	9.0	-28.7%
49.8	47.8	48.4	-2.7%
11.7	11.5	11.0	-5.7%
97.2	90.8	94.7	-2.6%
10.1			
26.0			
46.6	50.4	48.3	3.8%
37.4	41.1	40.1	7.2%
14.1	15.1	14.0	-0.7%
10.8	10.2	10.0	-7.7%
41.1	25.9	30.2	-26.6%
6.2	6.1	6.0	-3.4%
1.6	2.0	1.6	-0.3%
3.9	4.6	4.5	15.5%
6.6	9.6	8.0	21.9%
7.3	12.5	9.7	32.9%
30.9	22.4	22.6	-26.8%
17.9	14.6	14.6	-18.3%
14.7	10.5	10.7	-27.4%
10.5	7.2	7.4	-29.2%
483.0	456.6	453.0	-6.2%

3) Sales of products in Americas and EMEA

Unit: B¥

	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
Tarceva	25.5	17.9	-7.6	-29.9%
(US)	18.6	13.2	-5.5	-29.3%
(ex-US)	6.9	4.7	-2.2	-31.4%
Scan* (Americas)	40.6	35.4	-5.2	-12.9%
AmBisome (Americas)	5.5	4.8	-0.8	-13.7%
CRESEMBA (Americas)	0.8	2.5	1.7	197.0%
Qutenza (EMEA)	1.0	1.1	0.1	7.0%
DIFICLIR (EMEA)	1.3	1.1	-0.2	-17.5%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

FY15 Full Year	Initial Forecasts	Revised Forecasts	Change from FY15
	FY16 Full Year	FY16 Full Year	Change (%)
46.8			
33.8			
13.0			
76.2	70.1	67.7	-11.2%
10.9	9.8	9.7	-10.9%
2.6	5.0	5.8	122.3%
2.1			
2.6			

4) Sales in Americas and EMEA (Local currency)

Unit: M\$

Americas	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
Sales	1,912	1,963	51	2.6%
XTANDI	630	682	52	8.3%
US	611	649	37	6.1%
Americas (ex-US)	19	34	15	81.2%
Tarceva	210	170	-40	-18.9%
US	153	125	-28	-18.2%
ex-US	57	45	-12	-20.7%
VESIcare	273	263	-11	-3.9%
Myrbetriq	176	238	62	35.2%
Prograf	149	134	-15	-9.8%
Scan*	333	336	3	0.8%
MYCAMINE	55	57	2	3.0%
AmBisome	45	45	-0	-0.2%
CRESEMBA	7	24	17	243.5%

FY15 Full Year
3,788
1,272
1,235
37
389
281
108
530
380
288
634
109
91
22

Initial Forecasts	Revised Forecasts	Change from FY15
FY16 Full Year	FY16 Full Year	Change (%)
4,011	3,986	5.2%
1,544	1,470	15.5%
1,488	1,400	13.4%
56	70	87.1%
488	497	-6.3%
472	493	29.6%
245	259	-10.3%
637	660	4.0%
107	108	-0.2%
89	95	4.3%
45	56	160.2%

* Adenoscan + Lexiscan

Unit: M€

EMEA	FY15 APR. - SEP.	FY16 APR. - SEP.	Change	Change (%)
Sales	1,201	1,406	204	17.0%
XTANDI	233	345	112	47.9%
Eligard	65	66	1	1.2%
Vesicare	150	140	-10	-6.9%
BETMIGA	49	58	9	18.4%
Omnic	70	66	-5	-6.6%
Sales by Astellas	59	57	-2	-3.4%
Bulk and Royalties	11	8	-3	-24.4%
Prograf	308	315	7	2.3%
Sales by Astellas	297	302	5	1.6%
Advagraf	117	127	10	8.5%
Exports to third parties	11	14	2	21.7%
MYCAMINE	42	47	6	13.3%
Qutenza	7	9	2	22.3%
DIFICLIR	10	9	-1	-5.7%

FY15 Full Year
2,484
533
131
300
101
139
116
23
609
588
234
21
85
16
20

Initial Forecasts	Revised Forecasts	Change from FY15
FY16 Full Year	FY16 Full Year	Change (%)
2,717	2,763	11.3%
767	745	39.8%
138	129	-1.6%
259	279	-7.2%
146	125	23.4%
127	130	-6.3%
109	114	-2.4%
18	17	-26.6%
609	610	0.2%
589	590	0.3%
20	21	-3.2%
90	88	4.1%

- EMEA: Europe, Middle East and Africa

9.Consolidated statements of financial position

Unit: B¥

	31-Mar-16	30-Sep-16	
	Amount	Amount	Change
Assets	1,799.3	1,713.2	-86.2
Non-current assets	901.8	838.5	-63.3
Property, plant and equipment	201.0	182.7	-18.2
Goodwill	152.9	137.2	-15.7
Other intangible assets	335.7	317.8	-17.9
Trade and other receivables	24.1	28.0	3.9
Investments in associates and joint ventures	2.4	2.5	0.1
Deferred tax assets	81.5	74.2	-7.3
Other financial assets	89.4	82.8	-6.6
Other non-current assets	14.8	13.2	-1.5
Current assets	897.5	874.7	-22.8
Inventories	161.7	157.4	-4.2
Trade and other receivables	327.6	316.2	-11.4
Income tax receivable	16.4	5.9	-10.5
Other financial assets	14.4	12.0	-2.4
Other current assets	17.2	16.8	-0.4
Cash and cash equivalents	360.0	366.3	6.3
Assets held for sale	0.2	-	-0.2

- Due to the adjustments of the provisional fair value for the acquisition of Ocata Therapeutics, Inc. (The company name was changed to Astellas Institute for Regenerative Medicine in May 2016.), consolidated statement of financial position as of 31 March, 2016 was retrospectively revised. For the details, refer to Financial Results P.22

Unit: B¥

	31-Mar-16	30-Sep-16	
	Amount	Amount	Change
Equity and Liabilities	1,799.3	1,713.2	-86.2
Equity	1,259.2	1,227.3	-32.0
Equity attributable to owners of the parent	1,259.2	1,227.3	-32.0
Share capital	103.0	103.0	-
Capital surplus	176.9	177.0	0.1
Treasury shares	-157.1	-47.3	109.8
Retained earnings	973.1	941.2	-31.8
Other components of equity	163.4	53.4	-110.0
Liabilities	540.1	485.9	-54.2
Non-current liabilities	126.8	102.4	-24.4
Trade and other payables	1.6	0.9	-0.7
Retirement benefit liabilities	39.8	40.8	1.0
Provisions	7.1	4.9	-2.2
Other financial liabilities	0.7	0.8	0.1
Other non-current liabilities	77.6	55.0	-22.6
Current liabilities	413.4	383.5	-29.8
Trade and other payables	181.6	154.1	-27.4
Income tax payable	19.3	9.7	-9.6
Provisions	89.9	88.3	-1.6
Other financial liabilities	1.5	34.6	33.1
Other current liabilities	121.1	96.9	-24.2

10. Employees

Number of employees

	FY15 2Q End	FY16 2Q End
Total	17,352	17,215
Japan	7,300	7,070
Americas	2,957	2,936
EMEA	4,727	4,753
Asia and Oceania	2,368	2,456
Total Medical Representatives	6,220	5,980

- EMEA: Europe, Middle East and Africa

FY15 FY End
17,217
7,056
3,062
4,726
2,373
6,000

11. Shareholders

	FY15 2Q End	FY16 2Q End
Banks	30.5%	32.0%
Securities	3.6%	3.0%
Other companies	3.4%	3.5%
Foreign companies	51.4%	51.6%
Individuals and others	8.2%	8.6%
Treasury Stock*	2.9%	1.3%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust

[Three months ended September 30, 2016]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Sales	337.8	-1.7%	313.9	-8.7%
Cost of sales	71.5	-20.7%	74.7	-4.6%
Ratio to Sales	21.2%		23.8%	
Gross profit	266.3	5.0%	239.2	-9.9%
SG&A expenses	111.9	-5.7%	109.0	-10.0%
Ratio to Sales	33.1%		34.7%	
Advertising and Sales Promotion	35.8	-13.9%	33.4	-19.9%
Personnel expenses	43.5	-3.5%	42.0	-9.2%
Other	32.6	1.9%	33.6	1.3%
R&D expenses	51.0	-8.9%	48.6	-13.2%
Ratio to Sales	15.1%		15.5%	
Amortisation of intangible assets	9.0	-17.5%	8.7	-20.8%
Share of profits/losses of associates and joint ventures	-0.4	-	-0.3	-
Other income	0.2	-81.8%	0.1	-44.0%
Gain on sales of property, plant and equipment	0.0	-89.6%	0.0	-89.8%
Other expense	1.3	-81.7%	8.5	22.8%
Loss on sales and disposal of property, plant and equipment	0.1	39.8%	0.1	-53.2%
Impairment losses	-	-	7.6	-
Net foreign exchange losses	0.4	-	0.1	-97.8%
Operating profit	92.9	50.0%	64.2	-9.2%
Ratio to Sales	27.5%		20.4%	
Finance income	1.2	-79.8%	1.2	-84.0%
Gain on sales of available-for-sale financial assets	0.7	-88.1%	0.9	-85.8%
Finance expense	0.9	225.1%	0.8	166.0%
Impairment losses for available-for-sale financial assets	0.3	888.3%	0.1	14.2%
Profit before tax	93.2	37.7%	64.6	-16.9%
Ratio to Sales	27.6%		20.6%	
Income tax expense	26.6	15.3%	16.1	-17.0%
Profit for the period	66.6	49.3%	48.5	-16.9%
Ratio to Sales	19.7%		15.4%	
Comprehensive income	-34.0	-	36.7	11.0%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Sales	337.8	-1.7%	313.9	-8.7%
Cost of sales	71.5	-20.7%	74.7	-4.6%
Ratio to Sales	21.2%		23.8%	
Gross profit	266.3	5.0%	239.2	-9.9%
SG&A expenses	111.9	-5.7%	109.0	-10.0%
Ratio to Sales	33.1%		34.7%	
Advertising and Sales Promotion	35.8	-13.9%	33.4	-19.9%
Personnel expenses	43.5	-3.5%	42.0	-9.2%
Other	32.6	1.9%	33.6	1.3%
R&D expenses	51.0	-8.9%	48.6	-13.2%
Ratio to Sales	15.1%		15.5%	
Amortisation of intangible assets	9.0	-17.5%	8.7	-20.8%
Share of profits/losses of associates and joint ventures	-0.4	-	-0.3	-
Operating profit	94.0	38.5%	72.5	-6.3%
Ratio to Sales	27.8%		23.1%	
Finance income	0.6	2.8%	0.2	-67.8%
Finance expense	0.6	624.3%	0.7	213.0%
Profit before Tax	93.9	37.5%	72.1	-7.5%
Ratio to Sales	27.8%		23.0%	
Income tax expense	26.8	15.1%	18.6	-1.7%
Profit for the period	67.1	49.1%	53.4	-9.3%
Ratio to Sales	19.9%		17.0%	

3. Sales by Region

Unit: B¥

		FY16			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Sales		337.8	-1.7%	313.9	-8.7%
Japan		124.2	-1.1%	113.0	-7.0%
	Ratio to Sales	36.8%		36.0%	
Americas		107.6	-6.3%	99.1	-16.1%
	Ratio to Sales	31.8%		31.6%	
EMEA		85.3	4.4%	80.8	0.3%
	Ratio to Sales	25.3%		25.7%	
Asia and Oceania		20.7	-3.8%	21.1	-11.0%
	Ratio to Sales	6.1%		6.7%	

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

4. Addition to Property, Plant and Equipment Depreciation/Amortisation

Unit: B¥

		FY16			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Addition to Property, Plant and Equipment					
	Consolidated	3.9	-69.2%	5.0	-12.9%
Depreciation (PP&E)					
	Consolidated	5.5	9.9%	5.4	2.9%
Amortisation (Intangible Assets) *					
	Consolidated	10.4	-15.4%	10.2	-18.7%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1) Sales of global products

Unit: B¥

	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	64.2	8.7%	61.7	-2.4%
US	35.7	-1.4%	32.6	-14.8%
ex-US	28.5	24.8%	29.1	16.4%
Japan	6.1	-10.7%	5.7	-9.0%
Americas (ex-US)	1.8	70.0%	1.8	45.1%
EMEA	20.0	37.0%	20.8	22.8%
Asia and Oceania	0.7	62.5%	0.9	47.4%
Eligard	4.4	-0.1%	3.4	-21.8%
EMEA	4.4	-0.6%	3.4	-22.4%
Asia and Oceania	0.1	59.5%	0.1	27.9%
Vesicare	30.4	-14.0%	29.4	-14.5%
Japan	7.0	1.7%	6.0	-6.7%
Americas	13.6	-20.5%	14.1	-13.3%
EMEA	8.7	-14.8%	7.9	-22.3%
Asia and Oceania	1.2	-3.3%	1.2	-15.7%
Betanis/Myrbetriq/BETMIGA	23.6	30.1%	22.1	10.9%
Japan	6.4	32.5%	5.9	21.5%
Americas	12.9	31.4%	12.1	4.5%
EMEA	3.5	6.4%	3.4	0.9%
Asia and Oceania	0.7	606.9%	0.7	351.4%
Harnal/Omnice	12.1	-14.6%	11.3	-12.3%
Sales by Astellas	11.5	-13.3%	11.0	-11.3%
Japan	2.6	-25.1%	2.3	-30.7%
EMEA	3.7	-22.5%	3.1	-5.4%
Asia and Oceania	5.2	3.3%	5.3	-5.2%
Bulk and Royalties	0.6	-34.4%	0.4	-33.1%
Prograf	49.4	-1.9%	44.8	-17.4%
Sales by Astellas	48.7	-2.4%	43.9	-17.5%
Japan (Including Graceptor)	12.9	1.4%	11.9	-6.2%
Americas	7.7	-8.4%	6.4	-33.8%
EMEA	19.0	-2.8%	16.6	-19.0%
Advagraf	7.9	5.1%	7.1	-14.3%
Asia and Oceania	9.0	-1.3%	9.0	-12.9%
Exports to third parties	0.8	45.6%	0.9	-13.7%
Funguard/MYCAMINE	10.0	-2.5%	10.1	-6.5%
Japan	2.7	-7.0%	2.9	-7.0%
Americas	3.1	-4.9%	2.9	-16.8%
EMEA	2.8	-2.8%	2.8	1.1%
Asia and Oceania	1.5	14.9%	1.5	4.2%

- Sales of products in Japan are shown in a gross sales basis.

- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

<Global products>	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.1	-10.7%	5.7	-9.0%
Vesicare	7.0	1.7%	6.0	-6.7%
Betanis	6.4	32.5%	5.9	21.5%
Harnal	2.6	-25.1%	2.3	-30.7%
Prograf (Including Graceptor)	12.9	1.4%	11.9	-6.2%
Funguard	2.7	-7.0%	2.9	-7.0%
<Local products in Japan>				
Micardis [Family]	24.7	-0.4%	22.1	-6.8%
Micombi	2.5	-4.8%	2.2	-10.3%
Micamlo	6.8	5.2%	6.2	-1.2%
Celecox	12.4	4.9%	11.7	1.2%
Symbicort	9.8	9.3%	8.8	3.6%
Bonoteo	3.6	-0.8%	3.3	-1.3%
Geninax	2.5	-12.5%	1.8	-9.3%
Vaccines	3.8	-42.4%	7.3	-1.5%
Argamate	1.5	-0.4%	1.4	-6.8%
Kiklin	0.4	-1.6%	0.4	-10.3%
Gonax	1.1	14.7%	1.1	10.7%
Cimzia	1.9	20.8%	1.9	18.4%
Suglat	2.3	14.9%	2.3	58.2%
Lipitor	6.4	-22.8%	5.7	-27.8%
Myslee	3.9	-15.8%	3.7	-19.9%
Gaster	3.0	-24.6%	2.6	-30.5%
Seroquel	2.2	-25.3%	1.8	-32.1%
Total Rx Sales In Japanese market	114.8	-6.1%	107.0	-9.1%

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas and EMEA

Unit: B¥

	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Tarceva	9.4	-28.4%	8.5	-31.5%
(US)	6.8	-30.2%	6.4	-28.4%
(ex-US)	2.6	-23.3%	2.1	-39.5%
Scan* (Americas)	19.3	-7.3%	16.1	-18.8%
AmBisome (Americas)	2.4	-12.9%	2.3	-14.6%
CRESEMBA (Americas)	1.3	346.4%	1.2	120.7%
Qutenza (EMEA)	0.6	10.3%	0.5	3.4%
DIFICLIR (EMEA)	0.6	-6.9%	0.5	-27.6%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit: M\$

Americas	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Sales	995	5.2%	968	0.2%
XTANDI	347	12.9%	336	3.9%
US	330	10.7%	318	1.7%
Americas (ex-US)	16	90.8%	17	72.9%
Tarceva	87	-19.6%	83	-18.1%
US	63	-21.6%	62	-14.5%
ex-US	24	-13.9%	21	-27.4%
VESicare	126	-10.7%	137	3.3%
Myrbetriq	119	47.5%	119	24.7%
Prograf	71	2.8%	63	-20.8%
Scan	178	4.0%	158	-2.7%
MYCAMINE	29	6.7%	28	-0.6%
AmBisome	23	-2.2%	23	1.9%
CRESEMBA	12	400.9%	12	162.7%

* Adenoscan + Lexiscan

Unit: M€

EMEA	FY16			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Sales	699	14.8%	706	19.3%
XTANDI	164	50.6%	181	45.5%
Eligard	36	9.3%	30	-7.0%
Vesicare	71	-6.3%	69	-7.4%
BETMIGA	29	16.9%	29	20.0%
Omnice	35	-16.9%	31	8.7%
Sales by Astellas	30	-14.8%	28	13.2%
Bulk and Royalties	5	-27.8%	3	-18.6%
Prograf	162	8.2%	153	-3.2%
Sales by Astellas	156	6.8%	146	-3.4%
Advagraf	65	15.6%	62	2.1%
Exports to third parties	6	59.8%	7	1.8%
MYCAMINE	23	6.9%	24	20.0%
Qutenza	5	21.3%	4	23.4%
DIFICLIR	5	2.4%	4	-13.5%

- EMEA: Europe, Middle East and Africa